Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Decreases By 34.4%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNTGet Rating) was the recipient of a large drop in short interest in April. As of April 30th, there was short interest totalling 82,100 shares, a drop of 34.4% from the April 15th total of 125,200 shares. Currently, 0.7% of the shares of the company are short sold. Based on an average daily trading volume, of 41,500 shares, the days-to-cover ratio is presently 2.0 days.

Xtant Medical stock opened at $0.51 on Friday. Xtant Medical has a 52 week low of $0.48 and a 52 week high of $2.38. The company has a current ratio of 3.81, a quick ratio of 2.27 and a debt-to-equity ratio of 0.41. The company has a market cap of $44.63 million, a price-to-earnings ratio of -5.68 and a beta of 1.10.

Xtant Medical (NYSEAMERICAN:XTNTGet Rating) last posted its earnings results on Tuesday, March 8th. The medical device company reported ($0.03) EPS for the quarter. Xtant Medical had a negative return on equity of 22.21% and a negative net margin of 12.63%. The firm had revenue of $13.97 million for the quarter.

Several large investors have recently bought and sold shares of the stock. Midwest Professional Planners LTD. bought a new stake in shares of Xtant Medical in the 1st quarter worth approximately $28,000. Virtu Financial LLC raised its holdings in shares of Xtant Medical by 135.9% in the 4th quarter. Virtu Financial LLC now owns 58,037 shares of the medical device company’s stock worth $33,000 after purchasing an additional 33,438 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Xtant Medical by 6.0% in the 4th quarter. Renaissance Technologies LLC now owns 721,600 shares of the medical device company’s stock worth $404,000 after purchasing an additional 40,800 shares during the period. Crescent Grove Advisors LLC bought a new stake in shares of Xtant Medical in the 4th quarter worth approximately $91,000. Finally, State Street Corp bought a new stake in shares of Xtant Medical in the 2nd quarter worth approximately $37,000. 92.39% of the stock is currently owned by institutional investors.

About Xtant Medical (Get Rating)

Xtant Medical Holdings, Inc develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix.

Recommended Stories

Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.